AlphAIAlphAI — Financial news for AI agents
bioworld.comSEP 282 min read$MRK

Merck licenses SPR-2015 from China’s Scibrunch in $2B+ deal

Merck & Co. Inc. has licensed the preclinical drug SPR-2015 from Scibrunch Therapeutics Co. Ltd. for a potential $2.13 billion. The deal includes $400 million upfront and further milestone payments for development and commercialization in multiple indications.

Original reporting
bioworld.com
Published Sep 28, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Merck licenses SPR-2015 from China’s Scibrunch in $2B+ deal — source image
Source · bioworld.com
Decision brief

The 30-second read

$MRKBullishHigh
01

Why it matters

The $2.13 billion potential deal size is material for Merck's pipeline and earnings outlook, likely prompting a positive stock move.

02

Market read

First‑report of a multi‑billion licensing deal for a leading pharma company, with immediate trading relevance.

03

What to watch

Milestone payments are contingent on development success; regulatory and clinical risk remain high.

Relevance 9/10Novelty 9/10Timing: immediate

Background

Merck's licensing agreement targets a preclinical oral KRAS G12D inhibitor, a high‑interest target in oncology.

Company-level read

Ticker impact

$MRKBullishHigh confidence
Context

Merck announced an exclusive global license deal with Scibrunch Therapeutics valued up to $2.13 billion, including $400 million upfront.

Expected impact

potential upside as investors price in the $400 million upfront and future milestone payments

Evidence & confidence

Large‑cap licensing agreements of this magnitude are rare and materially affect earnings outlook, prompting a positive market reaction.

Market effects

Sector

Strengthens the oncology/biotech sector as Merck secures a novel KRAS G12D inhibitor platform.

Regional

May boost US pharma sentiment and could influence peer biotech valuations.

Global

Highlights growing cross‑border collaborations in oncology drug development.

Counterpoint

What could challenge this read

If the preclinical candidate fails later stages, the upfront payment may be the only benefit, limiting upside.

Key entities

  • company
    Merck & Co. Inc.

    US‑listed pharmaceutical giant (ticker MRK).

  • company
    Scibrunch Therapeutics Co. Ltd.

    Private Chinese biotech partner.

Read at source← All news

Related articles

SEP 28
$MRKMedAI 8/10

Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer

Daiichi Sankyo and Merck withdrew their FDA application for accelerated approval of I-DXd (ifinatamab deruxtecan) in small cell lung cancer. The FDA indicated the data did not meet the requirements for accelerated approval. The companies will focus on the ongoing phase 3 IDeate-Lung02 trial, which has faced delays due to safety concerns. I-DXd is also being tested in other cancer types.

managedhealthcareexecutive.com2 min
SEP 28
$MRKHighAI 8/10

Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy

Merck (MRK) and Daiichi Sankyo withdrew their FDA filing for ifinatamab deruxtecan, a lung cancer therapy, due to insufficient data. They continue evaluating it in late-stage studies. MRK's shares are up 41% year-to-date. This is the second withdrawal under their 2023 partnership.

zacks.com2 min
SEP 28
$MRKMed

Merck’s Forward P/E Nearly Doubled to 17x in a Year. Here’s What Its Pipeline Must Deliver by 2030

Merck (MRK) and Daiichi Sankyo withdrew a U.S. approval application for their investigational cancer drug, citing insufficient data. Merck's stock is at $148.74, with a mid-target of $166 and a potential 12% total return. The company's pipeline is estimated to deliver $70B+ by the mid-2030s, but recent setbacks highlight risks. Analysts' FY2030 revenue estimates have risen to around $76B.

tikr.com3 min
SEP 28
$MRKMedAI 9/10

Merck closes SciBrunch KRAS licence for up to US$2.13B

Merck & Co. has closed a licence agreement with SciBrunch Therapeutics for worldwide rights to a preclinical KRAS G12D cancer drug, SPR2015, for up to $2.13B, including a $400M upfront payment. The deal includes potential milestone payments tied to development and commercialization. Merck shares traded at $147.79 on Sept. 28, with a $400M pre-tax charge expected in Q3 2026 results.

mugglehead.com2 min